# EDGAR Filing Document

**Accession Number:** 0000832489
**File Stem:** 0000000000-26-003924
**Filing Date:** 2026-4
**Character Count:** 2465
**Document Hash:** 365d510d461b6e29e2d8468123aaaa34
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-003924.hdr.sgml**: 20260519

**ACCESSION NUMBER**: 0000000000-26-003924

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260417

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GeoVax Labs, Inc.
- **CENTRAL INDEX KEY:** 0000832489
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870455038
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-295081

**BUSINESS ADDRESS:**
- **STREET 1:** 1955 LAKE PARK DRIVE
- **STREET 2:** SUITE 300
- **CITY:** SMYRNA
- **STATE:** GA
- **BUSINESS PHONE:** 678-384-7220

**MAIL ADDRESS:**
- **STREET 1:** 1955 LAKE PARK DRIVE
- **STREET 2:** SUITE 300
- **CITY:** SMYRNA
- **STATE:** GA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Geovax Labs, Inc.
- **DATE OF NAME CHANGE:** 20061002

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DAUPHIN TECHNOLOGY INC
- **DATE OF NAME CHANGE:** 19940826

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SUCCESSO INC
- **DATE OF NAME CHANGE:** 19910410
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001437749-26-012439

## Text-Extract

```

                                                           April 17, 2026

David A. Dodd
President & Chief Executive Officer
GeoVax Labs, Inc.
1955 Lake Park Drive, Suite 300
Smyrna, Georgia 30080

       Re: GeoVax Labs, Inc.
           Registration Statement on Form S-1
           Filed April 16, 2026
           File No. 333-295081
Dear David A. Dodd:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    F. Reid Avett, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._